Exploratory analysis of the economically justifiable price of nirsevimab for healthy late-preterm and term infants in Colombia.

the economically justifiable cost for nirsevimab in Colombia is between U$ 21 to U$ 44 per dose, depending on the willingness to pay used to decide its implementation. This result should encourage more studies in the region that optimize decision-making processes when incorporating this drug into the health plans of each country.